BACKGROUND/AIM: The aim of this study was to examine the efficacy and safety of direct oral anticoagulants for cancer-associated venous thromboembolism (VTE) in patients with active cancer. PATIENTS AND METHODS: This study included patients with advanced unresectable/metastatic upper gastrointestinal (GI) or hepatopancreatobiliary (HPB) cancers with high risks of VTE and bleeding. RESULTS: No significant differences were noted in potential bleeding factors between the rivaroxaban (n=105) and low-molecular-weight heparin (LMWH) (n=69) groups. Rivaroxaban exhibited similar risk of recurrent/aggravated VTE compared with LMWH (p=0.625) but increased risk of major bleeding (17.4% vs. 7.6%; p=0.072), clinically relevant bleeding (31.9% vs. 14.3%; p=0.019), and total bleeding (40.6% vs. 19%; p=0.010). The multivariate analysis regarded rivaroxaban as a significant factor for major bleeding (p=0.043) and clinically relevant bleeding (p=0.043). CONCLUSION: Rivaroxaban exhibits comparable efficacy but increases bleeding risks compared with LMWH in patients with active unresectable/metastatic upper GI tract or HPB cancers, requiring extra caution of higher major bleeding risks. Copyright
BACKGROUND/AIM: The aim of this study was to examine the efficacy and safety of direct oral anticoagulants for cancer-associated venous thromboembolism (VTE) in patients with active cancer. PATIENTS AND METHODS: This study included patients with advanced unresectable/metastatic upper gastrointestinal (GI) or hepatopancreatobiliary (HPB) cancers with high risks of VTE and bleeding. RESULTS: No significant differences were noted in potential bleeding factors between the rivaroxaban (n=105) and low-molecular-weight heparin (LMWH) (n=69) groups. Rivaroxaban exhibited similar risk of recurrent/aggravated VTE compared with LMWH (p=0.625) but increased risk of major bleeding (17.4% vs. 7.6%; p=0.072), clinically relevant bleeding (31.9% vs. 14.3%; p=0.019), and total bleeding (40.6% vs. 19%; p=0.010). The multivariate analysis regarded rivaroxaban as a significant factor for major bleeding (p=0.043) and clinically relevant bleeding (p=0.043). CONCLUSION:Rivaroxaban exhibits comparable efficacy but increases bleeding risks compared with LMWH in patients with active unresectable/metastatic upper GI tract or HPB cancers, requiring extra caution of higher major bleeding risks. Copyright
Authors: Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: Dominique Farge; Henri Bounameaux; Benjamin Brenner; Francis Cajfinger; Philippe Debourdeau; Alok A Khorana; Ingrid Pabinger; Susan Solymoss; James Douketis; Ajay Kakkar Journal: Lancet Oncol Date: 2016-10 Impact factor: 41.316
Authors: Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong Journal: N Engl J Med Date: 2010-12-03 Impact factor: 91.245
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Agnes Y Y Lee; Pieter W Kamphuisen; Guy Meyer; Rupert Bauersachs; Mette S Janas; Mikala F Jarner; Alok A Khorana Journal: JAMA Date: 2015-08-18 Impact factor: 56.272
Authors: Martin H Prins; Anthonie W A Lensing; Tim A Brighton; Roger M Lyons; Jeffrey Rehm; Mila Trajanovic; Bruce L Davidson; Jan Beyer-Westendorf; Ákos F Pap; Scott D Berkowitz; Alexander T Cohen; Michael J Kovacs; Philip S Wells; Paolo Prandoni Journal: Lancet Haematol Date: 2014-09-28 Impact factor: 18.959
Authors: Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544
Authors: Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Mercedes Salgado; Elena Brozos-Vázquez; Begoña Campos; Paula González-Villarroel; María Eva Pérez; María Lidia Vázquez-Tuñas; David Arias Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512